
Chinese General Practice ›› 2025, Vol. 28 ›› Issue (33): 4132-4139.DOI: 10.12114/j.issn.1007-9572.2024.0628
Special Issue: 心血管最新文章合辑
• Original Research • Previous Articles Next Articles
Received:2024-11-04
Revised:2025-05-20
Published:2025-11-20
Online:2025-09-17
Contact:
SU Haiyan
通讯作者:
苏海燕
作者简介:作者贡献:
王碧优提出主要研究目标,负责研究的构思与设计,撰写文章初稿,对研究内容进行验证,保证研究结果的可重复性;高鹰、苏海燕负责文章的指导与修订;尤俊方、刘莉负责管理元数据、数据整理及维护;张卿负责文章的质量控制。
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0628
| 组别 | 例数 | TG/HDL-C | TC/HDL-C | LDL-C/HDL-C | NLR | NMR | LMR | MHR | CRP(mg/L) |
|---|---|---|---|---|---|---|---|---|---|
| 低危组 | 4 718 | 0.88(0.56,1.36) | 3.55(3.00,4.19) | 2.23(1.74,2.74) | 1.67(1.32,2.10) | 7.93(6.52,9.59) | 4.74(3.88,5.81) | 0.27(0.20,0.36) | 0.69(0.34,1.48) |
| 中危组 | 1 575 | 1.26(0.86,1.91) | 4.02(3.44,4.67) | 2.56(2.06,3.07) | 1.67(1.33,2.16) | 7.48(6.25,8.96) | 4.48(3.57,5.56) | 0.33(0.25,0.42) | 1.00(0.54,2.02) |
| 高危组 | 1 225 | 1.33(0.95,1.98) | 4.21(3.53,4.78) | 2.70(2.17,3.16) | 1.81(1.41,2.37) | 7.58(6.32,9.03) | 4.18(3.37,5.22) | 0.37(0.29,0.46) | 1.22(0.61,2.47) |
| H值 | 684.12 | 550.39 | 421.29 | 48.82 | 57.81 | 170.65 | 613.21 | 333.74 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 1 Comparison of baseline characteristic in different 10-year ASCVD risk groups
| 组别 | 例数 | TG/HDL-C | TC/HDL-C | LDL-C/HDL-C | NLR | NMR | LMR | MHR | CRP(mg/L) |
|---|---|---|---|---|---|---|---|---|---|
| 低危组 | 4 718 | 0.88(0.56,1.36) | 3.55(3.00,4.19) | 2.23(1.74,2.74) | 1.67(1.32,2.10) | 7.93(6.52,9.59) | 4.74(3.88,5.81) | 0.27(0.20,0.36) | 0.69(0.34,1.48) |
| 中危组 | 1 575 | 1.26(0.86,1.91) | 4.02(3.44,4.67) | 2.56(2.06,3.07) | 1.67(1.33,2.16) | 7.48(6.25,8.96) | 4.48(3.57,5.56) | 0.33(0.25,0.42) | 1.00(0.54,2.02) |
| 高危组 | 1 225 | 1.33(0.95,1.98) | 4.21(3.53,4.78) | 2.70(2.17,3.16) | 1.81(1.41,2.37) | 7.58(6.32,9.03) | 4.18(3.37,5.22) | 0.37(0.29,0.46) | 1.22(0.61,2.47) |
| H值 | 684.12 | 550.39 | 421.29 | 48.82 | 57.81 | 170.65 | 613.21 | 333.74 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| 典型变量 | r值 | 特征值 | Wilks值 | F值 | P值 |
|---|---|---|---|---|---|
| 1 | 0.569 | 0.478 | 0.668 | 217.551 | <0.001 |
| 2 | 0.100 | 0.010 | 0.988 | 11.789 | <0.001 |
| 3 | 0.049 | 0.002 | 0.998 | 6.041 | <0.001 |
Table 2 Canonical correlation analysis between lipid ratios and inflammatory markers
| 典型变量 | r值 | 特征值 | Wilks值 | F值 | P值 |
|---|---|---|---|---|---|
| 1 | 0.569 | 0.478 | 0.668 | 217.551 | <0.001 |
| 2 | 0.100 | 0.010 | 0.988 | 11.789 | <0.001 |
| 3 | 0.049 | 0.002 | 0.998 | 6.041 | <0.001 |
| 变量 | U1 | U2 |
|---|---|---|
| X1(TG/HDL-C) | 1.172 | 1.998 |
| X2(TC/HDL-C) | -1.274 | -3.984 |
| X3(LDL-C/HDL-C) | 1.493 | 2.366 |
Table 3 The standardized correlation coefficient between lipid ratios and comprehensive variable of lipid ratios
| 变量 | U1 | U2 |
|---|---|---|
| X1(TG/HDL-C) | 1.172 | 1.998 |
| X2(TC/HDL-C) | -1.274 | -3.984 |
| X3(LDL-C/HDL-C) | 1.493 | 2.366 |
| 变量 | V1 | V2 |
|---|---|---|
| Y1(NLR) | -0.355 | 0.495 |
| Y2(NMR) | 0.435 | 0.335 |
| Y3(LMR) | 0.081 | -0.395 |
| Y4(MHR) | 1.117 | 0.141 |
| Y5(CRP) | 0.009 | -0.565 |
Table 4 The standardized correlation coefficient between inflammatory markers and comprehensive variable of inflammatory markers
| 变量 | V1 | V2 |
|---|---|---|
| Y1(NLR) | -0.355 | 0.495 |
| Y2(NMR) | 0.435 | 0.335 |
| Y3(LMR) | 0.081 | -0.395 |
| Y4(MHR) | 1.117 | 0.141 |
| Y5(CRP) | 0.009 | -0.565 |
| 分组 | 典型变量 | r值 | 特征值 | Wilks值 | F值 | P值 |
|---|---|---|---|---|---|---|
| 低危组 | 1 | 0.573 | 0.490 | 0.661 | 140.403 | <0.001 |
| 2 | 0.110 | 0.012 | 0.984 | 9.263 | <0.001 | |
| 3 | 0.060 | 0.004 | 0.996 | 5.665 | 0.001 | |
| 中危组 | 1 | 0.552 | 0.439 | 0.680 | 43.178 | <0.001 |
| 2 | 0.142 | 0.020 | 0.979 | 4.166 | <0.001 | |
| 3 | 0.029 | 0.001 | 0.999 | 0.446 | 0.720 | |
| 高危组 | 1 | 0.496 | 0.326 | 0.739 | 25.898 | <0.001 |
| 2 | 0.135 | 0.019 | 0.980 | 3.059 | 0.002 | |
| 3 | 0.038 | 0.001 | 0.999 | 0.597 | 0.617 |
Table 5 Canonical correlation analysis between lipid ratios and inflammatory markers in different 10-year ASCVD risk groups
| 分组 | 典型变量 | r值 | 特征值 | Wilks值 | F值 | P值 |
|---|---|---|---|---|---|---|
| 低危组 | 1 | 0.573 | 0.490 | 0.661 | 140.403 | <0.001 |
| 2 | 0.110 | 0.012 | 0.984 | 9.263 | <0.001 | |
| 3 | 0.060 | 0.004 | 0.996 | 5.665 | 0.001 | |
| 中危组 | 1 | 0.552 | 0.439 | 0.680 | 43.178 | <0.001 |
| 2 | 0.142 | 0.020 | 0.979 | 4.166 | <0.001 | |
| 3 | 0.029 | 0.001 | 0.999 | 0.446 | 0.720 | |
| 高危组 | 1 | 0.496 | 0.326 | 0.739 | 25.898 | <0.001 |
| 2 | 0.135 | 0.019 | 0.980 | 3.059 | 0.002 | |
| 3 | 0.038 | 0.001 | 0.999 | 0.597 | 0.617 |
| 分组 | 变量 | U1 | U2 |
|---|---|---|---|
| 低危组 | X1(TG/HDL-C) | 1.111 | -1.913 |
| X2(TC/HDL-C) | -1.446 | 5.599 | |
| X3(LDL-C/HDL-C) | 1.633 | -4.029 | |
| 中危组 | X1(TG/HDL-C) | 1.582 | -2.193 |
| X2(TC/HDL-C) | -1.576 | 3.744 | |
| X3(LDL-C/HDL-C) | 1.592 | -2.029 | |
| 高危组 | X1(TG/HDL-C) | 1.016 | -1.105 |
| X2(TC/HDL-C) | -0.565 | 1.122 | |
| X3(LDL-C/HDL-C) | 0.925 | 0.011 |
Table 6 The standardized correlation coefficient between lipid ratios and comprehensive variable of lipid ratios in different 10-year ASCVD risk groups
| 分组 | 变量 | U1 | U2 |
|---|---|---|---|
| 低危组 | X1(TG/HDL-C) | 1.111 | -1.913 |
| X2(TC/HDL-C) | -1.446 | 5.599 | |
| X3(LDL-C/HDL-C) | 1.633 | -4.029 | |
| 中危组 | X1(TG/HDL-C) | 1.582 | -2.193 |
| X2(TC/HDL-C) | -1.576 | 3.744 | |
| X3(LDL-C/HDL-C) | 1.592 | -2.029 | |
| 高危组 | X1(TG/HDL-C) | 1.016 | -1.105 |
| X2(TC/HDL-C) | -0.565 | 1.122 | |
| X3(LDL-C/HDL-C) | 0.925 | 0.011 |
| 分组 | 变量 | V1 | V2 |
|---|---|---|---|
| 低危组 | Y1(NLR) | -0.264 | -0.388 |
| Y2(NMR) | 0.370 | -0.377 | |
| Y3(LMR) | 0.159 | 0.568 | |
| Y4(MHR) | 1.099 | -0.145 | |
| Y5(CRP) | 0.028 | 0.420 | |
| 中危组 | Y1(NLR) | -0.496 | 0.237 |
| Y2(NMR) | 0.586 | -0.629 | |
| Y3(LMR) | 0.035 | 1.206 | |
| Y4(MHR) | 1.116 | -0.031 | |
| Y5(CRP) | -0.039 | 0.119 | |
| 高危组 | Y1(NLR) | -0.602 | -0.994 |
| Y2(NMR) | 0.644 | 0.224 | |
| Y3(LMR) | -0.008 | -0.222 | |
| Y4(MHR) | 1.110 | -0.188 | |
| Y5(CRP) | -0.017 | 0.782 |
Table 7 The standardized correlation coefficient between inflammatory markers and comprehensive variable of inflammatory markers in different 10-year ASCVD risk groups
| 分组 | 变量 | V1 | V2 |
|---|---|---|---|
| 低危组 | Y1(NLR) | -0.264 | -0.388 |
| Y2(NMR) | 0.370 | -0.377 | |
| Y3(LMR) | 0.159 | 0.568 | |
| Y4(MHR) | 1.099 | -0.145 | |
| Y5(CRP) | 0.028 | 0.420 | |
| 中危组 | Y1(NLR) | -0.496 | 0.237 |
| Y2(NMR) | 0.586 | -0.629 | |
| Y3(LMR) | 0.035 | 1.206 | |
| Y4(MHR) | 1.116 | -0.031 | |
| Y5(CRP) | -0.039 | 0.119 | |
| 高危组 | Y1(NLR) | -0.602 | -0.994 |
| Y2(NMR) | 0.644 | 0.224 | |
| Y3(LMR) | -0.008 | -0.222 | |
| Y4(MHR) | 1.110 | -0.188 | |
| Y5(CRP) | -0.017 | 0.782 |
| [1] |
马丽媛,王增武,樊静,等. 《中国心血管健康与疾病报告2021》要点解读[J]. 中国全科医学,2022,25(27):3331-3346.
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中国循环杂志,2023,38(3):237-271. DOI:10.3969/j.issn.1000-3614.2023.03.001.
|
| [6] |
郭才华,王启章,胡乔,等. 急性缺血性脑卒中患者脂肪因子Apelin、Vaspin、Leptin对出血转化的预测价值[J]. 心血管康复医学杂志,2021,30(3):269-273. DOI:10.3969/j.issn.1008-0074.2021.03.05.
|
| [7] |
|
| [8] |
|
| [9] | |
| [10] |
|
| [11] |
李梦兰,梁宾,曹树正,等. 系统性炎症指数在冠心病中的临床意义及诊断价值研究[J]. 国际检验医学杂志,2021,42(19):2329-2332.
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
中国心血管病风险评估和管理指南编写联合委员会. 中国心血管病风险评估和管理指南[J]. 中国循环杂志,2019,34(1):4-28. DOI:10.3969/j.issn.1000-3614.2019.01.002.
|
| [16] | |
| [17] |
中国心血管病风险评估和管理指南编写联合委员会,顾东风. 中国心血管病风险评估和管理指南[J]. 中国循环杂志,2019,34(1):4-28. DOI:10.3760/cma.j.issn.0253-9624.2019.01.004.
|
| [18] |
陈欣,王丹,刘佳莉,等. 不同风险预测模型评估高血压人群10年心血管疾病风险的比较[J]. 中华高血压杂志,2023,31(10):929-936. DOI:10.16439/j.issn.1673-7245.2023.10.008.
|
| [19] |
陈瑞芳,黄俏,杨永红,等. 基于China-PAR模型正常高值血压与心血管病风险相关性研究[J]. 中国老年保健医学,2023,21(2):98-102.
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
董荣静,石柔,董雪娥,等. 中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值与2型糖尿病患者颈动脉粥样硬化的相关性[J]. 中华临床医师杂志(电子版),2017,11(2):179-182. DOI:10.3877/cma.j.issn.1674-0785.2017.02.001.
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
张京. 外周血炎症指标与颈动脉粥样硬化的相关性研究[D]. 武汉:江汉大学,2023. DOI:10.27800/d.cnki.gjhdx.2023.000299.
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [1] | AN Yanhong, WANG Shidong, LI Xiaoran, GUO Jiayang, WANG Zhe, SHA Peilin, MENG Yijun, LI Xiaoxuan, SHI Xue, YU Zexing, XIAO Yonghua. Study on Risk Factors and Nomogram Prediction Model for Diabetic Kidney Disease: Based on Contrast-enhanced Ultrasound Technology [J]. Chinese General Practice, 2026, 29(21): 2995-3003. |
| [2] | SONG Zhenzhen, CHEN Yang, WANG Jiwen, LIU Huishan, SHEN Simeng, SUN Ying, CHEN Xing. Study of Maternal Risk Factors Associated with Neonatal Asphyxia in Late Preterm and Term Infants [J]. Chinese General Practice, 2026, 29(20): 2874-2878. |
| [3] | YANG Xiaofeng, LI Xianwen, WU Yanfeng, ZHANG Qian, CHEN Juan, ZHAO Fengjiao. Association of Serum Vascular Endothelial Cadherin Levels with the Risk of Post-stroke Cognitive Impairment in Patients with Acute Ischemic Stroke [J]. Chinese General Practice, 2026, 29(20): 2867-2873. |
| [4] | REYILAI· Maimaiti, ZHOU Yiran, WU Yun, LIU Zhencheng, LU Yaoqin, WU Haiyan. Association between Novel Obesity Indicators and Cardiovascular Disease Risk in Hypertensive Patients [J]. Chinese General Practice, 2026, 29(20): 2836-2845. |
| [5] | ZHAO Huili, LU Lina, ZHUO Ya, WANG Xin. Clinical Characteristics and Risk Factors for Recurrence of Cryptogenic Organizing Pneumonia [J]. Chinese General Practice, 2026, 29(19): 2648-2655. |
| [6] | JIAN Yingchun, ZENG Yongqin, ZHANG Haiping, WANG Zhengdi, AN Ke, YAN Rui. Recent Advances in Mitochondrial Dysfunction in Chronic Metabolic Diseases [J]. Chinese General Practice, 2026, 29(18): 2577-2584. |
| [7] | HU Min, LYU Xiangdong. Accuracy of Artificial Intelligence in Remote Electrocardiography Diagnosis [J]. Chinese General Practice, 2026, 29(18): 2498-2503. |
| [8] | LIU Daiyue, LIU Xincan, LAN Zhenzhen. Research Progress on Postprandial Hyperlipidemia and Its Therapeutic Approaches [J]. Chinese General Practice, 2026, 29(18): 2546-2553. |
| [9] | ZHEN Rui, GU Xufang, GAO Shengwei, ZHANG Bowen, REN Zhenjuan, YANG Ruixuan. Burden of Cardiovascular Diseases Attributable to Metabolic Risk Factors in China 1990—2021 and Projected Trends from 2022 to 2035 [J]. Chinese General Practice, 2026, 29(15): 2077-2083. |
| [10] | QIU Yanli, GAO Yongyin, BIAN Xueyan, WANG Xue, LI Yue. The Predictive Value of Estimated Pulse Wave Velocity for All-cause and Cardiovascular-related Mortality in Cancer Patients [J]. Chinese General Practice, 2026, 29(14): 1890-1897. |
| [11] | HU Jiaqi, LI Duan, FANG Hao, FAN Xingying, DU Wei, ZHOU Hanni. Study on Predictive Model of Non-genetic Risk Factors for Hyperuricemia in a Physical Examination Cohort [J]. Chinese General Practice, 2026, 29(10): 1324-1333. |
| [12] | YANG Xu, FAN Jieting, SONG Hongyan, FENG Panpan, HAO Jingyu, YAO Mi. Risk Assessment and Communication Strategies for Cardiovascular Diseases in Primary Care [J]. Chinese General Practice, 2026, 29(10): 1294-1299. |
| [13] | LI Qiuchun, SU Ping, PANG Jinhong, CHEN Qiaoqiao, ZHAO Yingying, HE Ruiyan, WANG Yue, CHEN Xueyu, QIAO Junpeng, CHI Weiwei. Association of Triglyceride Glucose Index with Cardiovascular Disease in Cardiovascular-Kidney-Metabolic Syndrome Stage 0-3 Population: a Prospective Cohort Study [J]. Chinese General Practice, 2026, 29(09): 1129-1136. |
| [14] | SUN Qinyu, DENG Yifan, YANG Tianxiao, FANG Zhen, JI Jun, HE Shenghu, ZHANG Jing. Clinical Study of HbA1c/ApoA-1, TyG-BMI and Their Combination to Predict the Severity of Coronary Artery Calcification [J]. Chinese General Practice, 2026, 29(09): 1137-1145. |
| [15] | PEI Zhiyi, ZHANG Xiaoxin, LIN Jiayi, ZHANG Xiangyi, KANG Xiaofeng. Systematic Review of the Quality and Application of Patient Decision Aids in Cardiovascular Disease Based on IPDAS 4.0 Criteria [J]. Chinese General Practice, 2026, 29(07): 945-952. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||